NovoRapid

ApprovedSmall molecule

AArecor Limited

NovoRapid is one of 70 small molecule programs targeting Oxidative Stress. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oxidative StressActive, not recruiting

Type 1 Diabetes MellitusActive, not recruiting

Oxidative StressApproved

Active, not recruiting

Type 1 Diabetes MellitusPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

249 competitors in Type 1 Diabetes Mellitus

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Phase 3

4 2

Symlin

AstraZeneca

Phase 3

3 3

Suglat

Astellas

Phase 3

1 4

Galvus

Novartis

Phase 3

1 5

Tecfidera

Biogen

Phase 3

1 6

Inpefa

LLexicon Pharmaceuticals

Phase 3

5 7

Atacand

Zinbryta

Simulect

Jardiance

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Infusion

NCT06532461

Clinical

Trials by Indication[1]

LAM3 trials

AT278 and NovoRapid® in Glucose Clamp Study

Completed·AArecor Limited·Phase 1·NCT04660305·38 enrolled

AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study

Completed·AArecor Limited·Phase 1·NCT05754424·41 enrolled

AT247, NovoRapid® and Fiasp® in Glucose Clamp Study

Completed·AArecor Limited·Phase 1·NCT03959514·18 enrolled

Type 1 Diabetes Mellitus1 trial

A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus

Completed·AAdocia·Phase 1/2·NCT03981627·44 enrolled

Trial1 trial

A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin Pump

Completed·AAdocia·Phase 1·NCT03179332·43 enrolled

Closed-Loop1 trial

Fast Advanced Closed-Loop Therapy

Completed·UUniversity of Ljubljana, Faculty of Medicine·N/A·NCT04853030·30 enrolled

Infusion1 trial

A Trial of Three- and Seven-days Insulin Infusions Set

Recruiting·SSteno Diabetes Center Copenhagen·N/A·NCT06532461·80 enrolled

1 more indication

Oxidative Stress1 trial

Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)

Completed·FFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud·Phase 4·NCT03328845·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for NovoRapid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NovoRapid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NovoRapid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arecor Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AArecor Limited

NovoRapid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

LAM3 trials

Type 1 Diabetes Mellitus1 trial

Trial1 trial

Closed-Loop1 trial

Infusion1 trial

Oxidative Stress1 trial

References

Drug Info

Quick Facts

Related News